Paratek's Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults- Published in NEJM
Shots:
- The P-III OPTIC and OASIS-1 studies involves assessing of Nuzyra (Omadacycline) vs moxifloxacin & linezolid in 386 & 645 patients with community acquired bacterial pneumonia (CABP) & acute bacterial skin and skin structure infections (ABSSSI) respectively
- OPTIC study results: ECR (81.1- vs 82.7%-); IACR @PTE (87.6%- vs 85.1%); TEAEs (6.0% vs 6.7%); OASIS-1 study: ECR (84.8% vs 85.5%); IACR @PTE (86.1% vs 83.6%); mortality rate (0.3% vs 0.6%)
- Nuzyra (qd- IV/oral) is an antibiotic- targeted for community-acquired bacterial pneumonia- acute bacterial skin and skin structure infections- also being evaluated in UTI & is approved by the US FDA for resistance diseases i.e CABP & ABSSSI
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com